SC mAbs: remodelling traditional anticancer therapy
Subcutaneous monoclonal antibodies are replacing traditional intravenous biotherapeutics and this switch offers opportunities to remodel cancer services through the advantages that subcutaneous formulations confer
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news